FDA Issues First EUAs for SARS-CoV-2 Serology Tests that Provide Quantitative Information About COVID-19 Antibodies

FDA maze of regulations
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

First EUAs of their kind make semi-quantitative measurement of SARS-CoV-2 antibodies possible.

The US Food and Drug Administration (FDA) issued two emergency use authorizations (EUAs) for COVID-19 serology tests that provide quantitative analysis of antibodies present in an individual’s blood. Both tests are semi-quantitative tests that do not provide a precise measurement of the quantity of antibodies but will provide an estimate of antibody concentrations. 

Both of the EUAs were announced by the FDA July 31, 2020, and were issued to Siemens. The EUAs are for theirADVIA Centaur COV2G and Atellica IM COV2G tests and open the opportunity for better understanding of immune response to COVID-19 and the duration of antibodies that could confer immunity for COVID-19.

“Being able to measure a patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection may be useful as we continue to learn more about the virus and what the existence of antibodies may mean,” said Timothy Stenzel, MD, PhD, Director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, as part of the FDA’s announcement. 

“There are still many unknowns about what the presence of SARS-CoV-2 antibodies may tell us about potential immunity, but today’s authorizations give us additional tools to evaluate those antibodies as we continue to research and study this virus,” Stenzel said. “Patients should not interpret results as telling them they are immune, or have any level of immunity, from the virus.”

Regulatory Resource:

FDA Press Release: FDA Authorizes First Tests that Estimate a Patient’s Antibodies from Past SARS-CoV-2 Infection

COVID-19 TESTING DATA

Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.

Sincerely,

Robert L. Michel
President, Founder
The Dark Intelligence Group